EBMT to track long-term outcome data for Yescarta ®

(European Society for Blood and Marrow Transplantation) The European Society for Blood and Marrow Transplantation (EBMT) announces a new collaboration with Kite, a Gilead Company, to study the long-term outcomes of patients treated with Yescarta ® (axicabtagene ciloleucel), a chimeric antigen receptor T cell (CAR T) therapy. Under the terms of the collaboration, EBMT will collect treatment and long-term safety and efficacy data for 20 years from patients treated with Yescarta ® in the EBMT registry for cellular therapy.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news